Nucleic Acid Aptamer Binding Rabbit IgG Antibody
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The preparation of antibodies, such as rabbit IgG antibodies, is labor-intensive and costly, and they often exhibit nonspecific binding properties, making them difficult to handle and requiring the use of immune animals, which raises animal welfare concerns.
Innovation Solution
A nucleic acid molecule with the ability to bind specifically to a rabbit IgG antibody is developed using the SELEX method, allowing for the selection of RNA pools that form complexes with the antibody, thereby overcoming the limitations of traditional antibody preparation methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are prepared by immunizing animals, then specific binding activity to antigen is achieved, but labor intensity and preparation cost increase significantly
Solution Approach 1:
The patent uses aptamers as simplified copies or alternatives to antibodies. Instead of using complex animal-derived antibodies, the invention employs nucleic acid molecules that replicate the binding function, thereby eliminating the need for animal immunization while maintaining specific binding activity.
Solution Approach 2:
The patent replaces the biological/chemical system of animal immunization with an in vitro selection process (SELEX method). This substitution transforms a complex biological process into a controllable biochemical procedure that can be performed without live animals, improving productivity and ethical compliance.
2Reliability
If antibodies are used for binding, then specific antigen recognition is achieved, but nonspecific binding to other proteins and containers occurs
Solution Approach 1:
The patent applies local quality by designing aptamers with highly specific local binding regions that interact only with the target antigen. The SELEX process selects for sequences with optimized local complementarity to the antigen, minimizing nonspecific interactions while maintaining strong specific binding.
Solution Approach 2:
The patent changes the fundamental parameter of binding molecule type from protein (antibody) to nucleic acid (aptamer). This parameter change fundamentally alters the binding characteristics, providing high specificity without the nonspecific binding issues inherent to antibodies.
3Measurement precision
If secondary antibodies with labeling compounds are prepared, then detection capability is enhanced, but preparation process complexity increases
Solution Approach 1:
The patent merges the binding function and detection function into a single aptamer molecule. By incorporating fluorescent or other detection labels directly onto the aptamer during the SELEX process or subsequent modification, the invention eliminates the need for separate secondary antibody preparation steps.
Solution Approach 2:
The patent uses aptamers as intermediaries that directly bind to the target antigen and can carry detection labels. This eliminates the need for the traditional sandwich assay format requiring both primary and secondary antibodies, simplifying the overall detection system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nucleic acid molecule achieves specific binding to rabbit IgG antibodies with high affinity, providing a more efficient and cost-effective alternative to traditional antibody preparation methods while reducing the need for immune animals.
Implementation Method 1
a nucleic acid molecule having an ability to bind to a rabbit IgG antibody
Implementation Method 2
capable of binding, in a binding mode such as hydrogen bond, to a high-molecular compound such as a protein
Data Source
Figure 1-1
Figure 1-2
Figure 1-3
AI summary
The present invention provides a nucleic acid molecule having an ability to bind to a rabbit anti-mouse IgG antibody, which can be prepared more easily than an antibody and has a binding ability equal to or higher than that of an antibody. The nucleic acid molecule according to the present invention may have the sequences set forth in SEQ ID NOS: 1 to 5. The nucleic acid molecule according to the present invention may be a nucleic acid having an ability to bind to a rabbit IgG antibody, which substantially has homology to its sequence. The nucleic acid molecule according to the present invention may have a binding constant (KD) of 1.18 × 10-7 (M) or less to the rabbit IgG antibody.